Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer
Authors
Keywords
Triple-negative breast cancer, Radiotherapy, Polo-like kinase 4, CFI-400945, Radiosensitization, Patient-derived organoids
Journal
BREAST
Volume 58, Issue -, Pages 6-9
Publisher
Elsevier BV
Online
2021-04-01
DOI
10.1016/j.breast.2021.03.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination
- (2020) Benjamin C. Chandler et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
- (2020) Pierre Loap et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
- (2019) Zachary W. Veitch et al. BRITISH JOURNAL OF CANCER
- Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
- (2019) Ye Yao et al. Cell Stem Cell
- CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases
- (2019) Nicholas B. Figura et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer
- (2018) Da Yao et al. Biochemistry and Cell Biology
- A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
- (2018) Norman Sachs et al. CELL
- Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers
- (2018) Masanori Kawakami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TREATMENT OUTCOMES OF BREAST CANCER LIVER METASTASIS TREATED WITH STEREOTACTIC BODY RADIOTHERAPY
- (2018) Cem Onal et al. BREAST
- Targeting the cell cycle in breast cancer: towards the next phase
- (2018) KL Thu et al. CELL CYCLE
- Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non–Small-Cell Lung Cancer
- (2017) Kenneth E. Rosenzweig et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Normal Tissue Injury From Irradiation
- (2017) Deborah E. Citrin et al. SEMINARS IN RADIATION ONCOLOGY
- Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma
- (2017) Simone Treiger Sredni et al. Oncotarget
- Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer
- (2016) Ryan A. Denu et al. BMC CANCER
- Clinical development of new drug–radiotherapy combinations
- (2016) Ricky A. Sharma et al. Nature Reviews Clinical Oncology
- Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts
- (2016) Ines Lohse et al. Oncotarget
- Targeting Mitosis in Cancer: Emerging Strategies
- (2015) Carmen Dominguez-Brauer et al. MOLECULAR CELL
- Numerical chromosomal instability mediates susceptibility to radiation treatment
- (2015) Samuel F. Bakhoum et al. Nature Communications
- Delayed Numerical Chromosome Aberrations in Human Fibroblasts by Low Dose of Radiation
- (2015) Yoon Cho et al. International Journal of Environmental Research and Public Health
- Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent
- (2014) Jacqueline M. Mason et al. CANCER CELL
- Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance
- (2014) Mihaela Marina Frontiers in Bioscience-Landmark
- The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
- (2014) Peter B. Sampson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer
- (2011) Kathrin Dellas Breast Care
- Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study
- (2011) Michael T. Milano et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines
- (2010) N. Niu et al. GENOME RESEARCH
- Prognostic factors for survival and intracerebral control after irradiation for brain metastases from gynecological cancer
- (2009) Dirk Rades et al. GYNECOLOGIC ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now